Reading OHI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OHI free→Reading OHI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OHI free→
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, but the capital stance is capital unfriendly. The sector backdrop is a headwind, and risk is moderate. Peer multiples imply a price about 112% below where it trades (it looks expensive on this basis); the read is rich. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $45.52. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $46 the market pays 22× p/e — above the 14× p/e peer median but in line with its own 22× history. That premium reflects a durable franchise our peer-anchored $22 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $48–$54. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 112% near-term growth, well above our forecast of about 15%. This describes what's priced in, not a forecast of the move.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Real Estate names rated neutral grew net income 53% of the time over the next year (vs 57% for the rest of the cohort, n=1968).
Over the trailing year it converted 21.40x of net income into operating cash flow. Historically, Real Estate names rated robust grew net income 59% of the time over the next year (vs 50% for the rest of the cohort, n=1399).
Most sensitive to real (inflation-adjusted) rates and long-term interest rates.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.49 → $0.49 (-0.2% / 30d). 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d, 3 maintained. 39% of analysts rate Buy.
2 PT revisions / 30d. Avg target 6.4% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$81.
How much price usually moves either way.
On a bad day, this stock has moved -$169.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,086.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
The signal changed to mixed. This indicates a shift in outlook. Risk remains moderate. The sector backdrop is a headwind, which may affect performance.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show if revenue growth continues. This is key for investors.
Confirms:Revenue growth exceeds 7% year over year in the Q2 earnings report.
Disproves:Revenue growth falls below 5% year over year in the Q2 earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
New CEO and CFO may enhance strategic execution.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of Form 8-K and Item 404(a) of Regulation S-K. Messrs. Gourmand, Ballew and Golem’s employment agreements will be amended as of the respective transition dates to reflect their new roles. Transition and Consulting Agreements In connection with Mr. Pickett’s departure and the transitioning of his responsibilities, the Company and its subsidiary OHI Asset Management LLC (“Omega Asset Management”) entered into a Transition Agreement and Release with Mr. Pickett effective as of May 19, 2026 (the…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$48.00 – $54.00 (median $50.00) · 5 analysts · as of 2026-06-16
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care REITs.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
OHI Omega Healthcare Investors | Typical Show detailsSector percentile: 70 of 100 | expensive | moderate |
WELL Welltower | Typical Show detailsSector percentile: 58 of 100 | expensive | low |
VTR Ventas | Typical Show detailsSector percentile: 40 of 100 | full | moderate |
DOC Healthpeak Properties | Above typical Show detailsSector percentile: 77 of 100 | fair | moderate |
AHR American Healthcare REIT | Below typical Show detailsSector percentile: 27 of 100 | expensive | moderate |
5 material management or governance events in the past 24 months, led by M&A activity. Historically, Real Estate names rated neutral grew net income 57% of the time over the next year (vs 55% for the rest of the cohort, n=5004).
Not investment advice. As of 2026-06-16.
via XLRE
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to provide a stable dividend per share of $0.67.
Focus on growing revenue through strategic initiatives.
Enhance net income through operational efficiencies and strategic growth.
Why it matters: Keeping or changing the dividend affects how investors feel and cash flow.
Confirms:Management says the dividend will stay at $0.67 per share.
Disproves:Dividend is cut or lowered below $0.67 per share.
Why it matters: A rise in net income shows good operations and helps reach growth goals.
Confirms:Q2 net income was over $151.0M, showing success in operations.
Disproves:Q2 net income was below $151.0M, showing problems in operations.
Why it matters: Changes in leadership can change the company's path. This can affect how investors feel.
Confirms:New CEO and CFO are announced with strong industry backgrounds.
Disproves:No new leaders are announced. This creates uncertainty.
Why it matters: Higher revenue shows growth and helps management focus on making more money.
Confirms:Q2 revenue reported above $322.9M, indicating strong growth.
Disproves:Q2 revenue reported below $322.9M, suggesting growth is stalling.
Why it matters: The sale will impact Omega's cash flow and ability to reinvest in growth.
Confirms:The sale of all 18 CommuniCare facilities for $480 million is done.
Disproves:The sale is delayed or canceled. This affects cash flow and investment plans.
of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Termination of a Material Definitive Agreement. On October 15, 2025, Omega Healthcare Investors, Inc. (“Omega”) redeemed all of the $600 million aggregate principal amount of its outstanding 5.250% Senior Notes due 2026 (the “Notes”). The Notes were originally issued under an Indenture dated as of September 23, 2015, as amended and supplemented, or the Indenture, by and among Omega, certain of its subsidiaries, as guarantors, and U.S. Bank Trust Company, National Association, as Trustee. …
Entry into a Material Definitive Agreement. Omega Credit Agreement On September 30, 2025, Omega Healthcare Investors, Inc. (“ Omega ”) entered into a new senior unsecured $2.3 billion credit facility, comprised of a $2.0 billion multicurrency revolving credit facility (“ Revolving Credit Facility ”) and a $300.0 million delayed draw term loan facility (the “ DDTL Credit Facility ” and together with the Revolving Credit Facility, the “ Credit Facility ”), replacing its previous senior unsecure…